HC Wainwright Expects Lower Earnings for Abeona Therapeutics

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities researchers at HC Wainwright decreased their Q3 2025 earnings estimates for Abeona Therapeutics in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.24) per share for the quarter, down from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $1.49 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.42 EPS.

ABEO has been the subject of several other reports. Alliance Global Partners reiterated a “buy” rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 15th. Stifel Nicolaus reduced their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Friday, May 16th. Finally, Oppenheimer raised their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Abeona Therapeutics has a consensus rating of “Buy” and an average price target of $19.50.

Abeona Therapeutics Trading Up 2.3%

ABEO opened at $7.00 on Wednesday. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.54. The company has a quick ratio of 4.90, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average of $6.26 and a 200-day moving average of $5.77. The stock has a market cap of $358.96 million, a PE ratio of 10.00 and a beta of 1.55.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, topping the consensus estimate of ($0.39) by $2.10. The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $21.71 million.

Institutional Trading of Abeona Therapeutics

A number of large investors have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. increased its stake in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares in the last quarter. Oxford Asset Management LLP bought a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $118,000. Northern Trust Corp lifted its position in Abeona Therapeutics by 6.6% during the fourth quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 11,478 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $341,000. Finally, Jane Street Group LLC lifted its holdings in shares of Abeona Therapeutics by 894.8% in the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock worth $732,000 after acquiring an additional 118,262 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling

In other news, SVP Brendan M. O’malley sold 17,428 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total value of $102,128.08. Following the completion of the sale, the senior vice president owned 360,817 shares in the company, valued at $2,114,387.62. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Faith L. Charles sold 10,738 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $62,924.68. Following the completion of the sale, the director owned 139,094 shares of the company’s stock, valued at approximately $815,090.84. This represents a 7.17% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 231,626 shares of company stock valued at $1,430,587 over the last 90 days. 6.90% of the stock is currently owned by company insiders.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.